Overcoming the bottlenecks in financing young biotech companies

Experiences from the Munich Cluster

Business & Finance, Finance & Investing, Finance
Cover of the book Overcoming the bottlenecks in financing young biotech companies by Sascha Berger, GRIN Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Sascha Berger ISBN: 9783638054720
Publisher: GRIN Publishing Publication: May 28, 2008
Imprint: GRIN Publishing Language: English
Author: Sascha Berger
ISBN: 9783638054720
Publisher: GRIN Publishing
Publication: May 28, 2008
Imprint: GRIN Publishing
Language: English

Diploma Thesis from the year 2007 in the subject Business economics - Investment and Finance, grade: 1,3, Technical University of Munich (KfW Stiftungslehrstuhl für Entrepreneurial Finance), 148 entries in the bibliography, language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seed-phase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proof-of-concept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Diploma Thesis from the year 2007 in the subject Business economics - Investment and Finance, grade: 1,3, Technical University of Munich (KfW Stiftungslehrstuhl für Entrepreneurial Finance), 148 entries in the bibliography, language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seed-phase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proof-of-concept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle.

More books from GRIN Publishing

Cover of the book Innovation in the context of 'Zotter Schokoladen-Manufaktur GmbH' by Sascha Berger
Cover of the book Pädagogik und Evolutionswissenschaften by Sascha Berger
Cover of the book Types of the sonnet in english and american literature by Sascha Berger
Cover of the book Maximilien Robespierre's Virtue and Terror by Sascha Berger
Cover of the book Hanseatic Architecture by Sascha Berger
Cover of the book Ryanair and its low cost flights in Europe by Sascha Berger
Cover of the book Spike Lee's 'Bamboozled': The Depiction of African-Americas in US Popular Film and Television and its Traditions by Sascha Berger
Cover of the book Besteuerung der Europäischen Aktiengesellschaft by Sascha Berger
Cover of the book Duty to report in accordance with IFRS 3 by Sascha Berger
Cover of the book Angel... And Other Myths by Sascha Berger
Cover of the book Eine ungewöhnliche Beziehung by Sascha Berger
Cover of the book Intercultural relationships and national identities in E.M. Forster´s novel 'A Passage to India' by Sascha Berger
Cover of the book Depoliticisation as an orthodox account of British economic policy since 1997 by Sascha Berger
Cover of the book How to make linguistics enjoyable? by Sascha Berger
Cover of the book What are the main implications of the 'shareholder' and 'stakeholder' models of corporate governance for the development of long-term human resource strategies? by Sascha Berger
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy